Exelixis, Inc. 2007 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Exelixis, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 28, 2007 (52-week year).
Business Overview: Exelixis is a biopharmaceutical company focused on discovering and developing small molecule drugs for cancer and other serious diseases. The company utilizes an integrated drug discovery platform and maintains strategic collaborations with major pharmaceutical partners (GlaxoSmithKline, Bristol-Myers Squibb, Genentech) to fund operations and share development risks. As of year-end, the company had no approved commercial products and relied on collaboration revenues and milestone payments.
Key Financial Metrics
| Metric | 2007 | 2006 |
|---|---|---|
| Total Revenues | $113.5 million | $98.7 million |
| Net Loss | $(86.4) million | $(101.5) million |
| Operating Loss | $(157.0) million | $(126.8) million |
| Research & Development Expenses | $225.4 million | $185.5 million |
| Cash and Cash Equivalents | $135.5 million | $123.4 million |
| Total Cash, Securities & Investments | $299.5 million | $263.2 million |
| Working Capital | $150.9 million | $150.8 million |
| Long-Term Debt (Convertible Loans) | $85.0 million | $85.0 million |
Note: The 2007 Net Loss was significantly reduced by non-recurring gains totaling $36.9 million from the sale of the plant trait business and an 80.1% interest in Artemis Pharmaceuticals GmbH.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 15% to $113.5 million, driven by higher amortization of upfront payments from new collaborations (Bristol-Myers Squibb and Genentech) and milestone achievements.
- Expense Increases: R&D expenses rose 22% to $225.4 million due to expanded clinical trial activities (Phase 1 and Phase 2) and increased personnel costs.
- Asset Dispositions: The company sold its plant trait business to Agrigenetics (Dow Chemical) for a net gain of $18.8 million and sold 80.1% of its German subsidiary, Artemis, for a net gain of $18.1 million. These transactions significantly improved the bottom-line net loss compared to the prior year.
- Collaboration Milestones: GlaxoSmithKline exercised its option to develop XL880 in December 2007. However, the $35.0 million selection milestone was offset against a prior 2005 payment, resulting in no immediate cash receipt or revenue recognition for this specific milestone.
Guidance, Outlook, and Risks
Outlook: Management anticipates continuing net losses and negative operating cash flow for the foreseeable future. The company expects current cash resources and collaboration funding to support operations for at least 12 months following the filing date. Future capital requirements will be substantial to fund clinical trials and potential repurchase of assets.
Key Risks and Contingencies:
- Liquidity and Financing: The company must raise additional capital to fund operations and meet financial covenants. A key covenant with GlaxoSmithKline requires maintaining working capital of at least $25.0 million and cash/investments of at least $50.0 million.
- Asset Repurchase Obligation: Exelixis has an exclusive option to repurchase three compounds (XL647, XL784, XL999) from Symphony Evolution, Inc. (SEI). The purchase price is $80.0 million plus 25% annual compound interest. GlaxoSmithKline declined to select XL647 and XL784, and Exelixis discontinued XL999. To retain rights to these assets, Exelixis must repurchase all three, requiring significant cash or stock issuance.
- Clinical Development Risk: Success depends on the safety and efficacy of product candidates in clinical trials. Failure in trials could delay or prevent commercialization and impact future milestone revenues.
- Collaboration Dependence: Revenues are heavily dependent on partners (Bristol-Myers Squibb, GlaxoSmithKline, Genentech). Termination or failure of these partners to achieve milestones would materially impact financial results.
Investor Verification Checklist
- SEI Repurchase Terms: Verify the current accrued interest on the $80.0 million Symphony Evolution investment and the timeline for the mandatory repurchase decision (June 2009 or 90 days after SEI cash drops below $5.0 million).
- GlaxoSmithKline Loan Covenants: Confirm ongoing compliance with the $25.0 million working capital and $50.0 million cash/investment covenants to avoid default on the $85.0 million convertible loan.
- Clinical Trial Status: Review the latest data for key Phase 2 candidates (XL647, XL880, XL820) and Phase 1 candidates to assess the probability of future milestone payments.
- Capital Raise Plans: Monitor for announcements regarding new equity offerings or debt financing required to fund the aggressive clinical pipeline and potential asset repurchases.
- Non-Recurring Gains: Distinguish between operating performance and the one-time gains from the sale of the plant trait business and Artemis when evaluating future profitability.